作者
Thomas Luke, Hua Wu, Jincun Zhao, Rudragouda Channappanavar, Christopher M Coleman, Jin-An Jiao, Hiroaki Matsushita, Ye Liu, Elena N Postnikova, Britini L Ork, Gregory Glenn, David Flyer, Gabriel Defang, Kanakatte Raviprakash, Tadeusz Kochel, Jonathan Wang, Wensheng Nie, Gale Smith, Lisa E Hensley, Gene G Olinger, Jens H Kuhn, Michael R Holbrook, Reed F Johnson, Stanley Perlman, Eddie Sullivan, Matthew B Frieman
发表日期
2016/2/17
期刊
Science translational medicine
卷号
8
期号
326
页码范围
326ra21-326ra21
出版商
American Association for the Advancement of Science
简介
As of 13 November 2015, 1618 laboratory-confirmed human cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection, including 579 deaths, had been reported to the World Health Organization. No specific preventive or therapeutic agent of proven value against MERS-CoV is currently available. Public Health England and the International Severe Acute Respiratory and Emerging Infection Consortium identified passive immunotherapy with neutralizing antibodies as a treatment approach that warrants priority study. Two experimental MERS-CoV vaccines were used to vaccinate two groups of transchromosomic (Tc) bovines that were genetically modified to produce large quantities of fully human polyclonal immunoglobulin G (IgG) antibodies. Vaccination with a clade A γ-irradiated whole killed virion vaccine (Jordan strain) or a clade B spike protein nanoparticle vaccine (Al-Hasa strain) resulted …
学术搜索中的文章
T Luke, H Wu, J Zhao, R Channappanavar… - Science translational medicine, 2016